Clinical
RSSArticles
-
The Pros and Cons of Central Venous Catheterization Sites
ABSTRACT AND COMMENTARY: Improper placement can lead to a deep vein thrombosis or a blood stream infection. Here's guidance on doing it right.
-
Blood Pressure Targets in Flux Again
Trial could be a game changer if the results are robust.
-
Finally, a Positive Outcomes Study for Platelet Function Testing
Platelet function testing-defined clopidogrel nonresponsiveness can be overcome by prasugrel treatment, and that this is a modifiable risk factor whose treatment can improve outcomes.
-
Slow Down, Save Lives? Rate Control in Atrial Fibrillation
Atrial fibrillation patients receiving beta-blockers or calcium channel blockers had lower risk of mortality compared to those not taking rate-control drugs, with the lowest mortality rate in the beta-blocker group, while digoxin use was associated with a higher risk of mortality.
-
Beta-blocker Dose More Important Than Heart Rate in Systolic Heart Failure
In chronic heart failure with reduced ejection fraction, titrating beta-blocker doses may confer a greater benefit than reducing heart rate.
-
Reduced Leaflet Motion in Bioprosthetic Valves
ABSTRACT & COMMENTARY: It's in a significant proportion of surgical and transcatheter bioprosthetic aortic valves by volume-rendered CT scans.
-
Between-arm Differences in BP Predict Peripheral Arterial Disease
An inter-arm systolic blood pressure difference of as little as 10 mmHg was associated with a doubling of the risk for peripheral arterial disease.
-
Uric Acid as a Predictor of Hypertension
Our currently defined levels of “normal” for uric acid may have to be reconsidered.
-
ACE Inhibitors vs ARBs for Hypertension
This data review would support using angiotensin-converting-enzyme inhibitors preferentially over angiotensin II receptor blockers in most patients with hypertension.
-
Difficult Choices in Long-term Osteoporosis Management
The greatest improvements in bone mineral density were seen in women who were assigned initially to a combination of denosumab and teriparatide and then switched to denosumab monotherapy.